SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

VTGN

Vistagen Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 18h ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Watch for Vistagen's revised Phase 3 protocol submission and any financing announcements, as the company's $7M market cap suggests limited cash runway to fund a registrational trial.

DirectionNeutral
Confidencemedium
Horizonmonths

fasedienol

▼ Bearish Named in this press release
Impact
Phase
Phase 3 (completed — two of three Phase 3 trials failed)
Time to market
Unknown — at least 3-5+ years if a new Phase 3 trial is required, with no guarantee of FDA acceptance of the proposed path
Next catalyst
None dated

What to watchFasedienol has now failed two consecutive Phase 3 trials (PALISADE-3 Dec 2025, PALISADE-4 June 2026). The stock traded at ~$2.04 before the PALISADE-4 miss and collapsed to ~$0.25, a ~$10M market cap. The company plans an FDA meeting for a potential new trial path, but the path to approval looks extremely long and uncertain. Watch for dilution risk as the company may need financing to fund any future trial.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.1844
T+0 close · Nov 9, 2026 · via day close
Latest settled
−0.05%
T+5 · $0.1843
Vs SPY
+1.64%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $0.1844entry
  2. T+1 · 7d ago −0.70%α −0.34% · $0.1831
  3. T+5 · 20h ago −0.05%α +1.64% · $0.1843
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vistagen announced constructive FDA feedback from a Type C meeting on fasedienol for social anxiety disorder, including endorsement of the LSAS as a primary endpoint and guidance on interim assessments. The company plans to submit a revised Phase 3 protocol focusing on the general SAD population. No approval, funding, or timeline was provided, and the company's $7M market cap raises significant financing risk.

Key Facts

  • FDA provided constructive feedback on using LSAS as primary endpoint in a future Phase 3 study for fasedienol in SAD.
  • FDA recommended interim assessments (eDiaries, patient surveys) to evaluate acute and longer-term effects.
  • Vistagen plans to submit a revised protocol focusing on the general SAD population, not just acute treatment.
  • FDA recognized fasedienol's reported safety profile and potential to benefit a broad SAD population.
  • No specific timeline, funding, or approval decision was announced; company has $7M market cap and no approved products.

Financial Impact

No financial impact stated; regulatory feedback is procedural and does not guarantee approval or funding.

Risk Factors

  • FDA feedback is non-binding; future Phase 3 results may not support approval.
  • Company has no approved products and very small market cap ($7M), raising significant financing risk.
  • No timeline provided for protocol submission or trial initiation; development may be delayed or halted.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398411

Track record

21 reports on VTGN

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
  2. Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
  3. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  5. Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
  6. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
  7. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
  8. Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  9. Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  10. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026